Fibronectin Scaffold Polypeptides for HIV Entry Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV therapies face challenges due to long-term toxicities, resistance development, and compliance issues, necessitating new anti-retroviral agents with improved safety and resistance barriers, as well as more convenient dosing regimens.
Innovation Solution
Development of polypeptides comprising a CD4 binding moiety, a gp41 binding moiety, and a HIV fusion peptide inhibitor, connected by linkers, which are based on a fibronectin scaffold domain protein, to inhibit HIV entry into cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-retroviral agents are used for long-term therapy, then HIV infection is controlled, but long-term toxicities and resistance development occur
Solution Approach 1:
The invention divides the HIV entry process into multiple targetable steps (CD4 binding, co-receptor binding, fusion) and uses separate polypeptide components to inhibit each step, thereby achieving comprehensive blockade without relying on a single drug mechanism that leads to resistance and toxicity
Solution Approach 2:
The invention creates composite polypeptides by fusing multiple functional domains (CD4 binding domain, co-receptor binding domain, fusion inhibitor domain) into single molecules, combining multiple mechanisms of action to prevent HIV entry through several simultaneous barriers, reducing the likelihood of resistance development
2Reliability
If combination therapy with multiple agents is used, then antiviral efficacy is improved, but compliance issues and treatment complexity increase
Solution Approach 1:
The invention merges multiple anti-HIV functional domains into single polypeptide molecules, combining the effects of what would traditionally require multiple separate drugs into one therapeutic agent, thereby simplifying the treatment regimen while maintaining or improving efficacy
Solution Approach 2:
The invented polypeptides perform multiple functions simultaneously (blocking CD4 binding, blocking co-receptor binding, and inhibiting fusion) within a single molecule, making them universal inhibitors that address multiple stages of HIV entry without requiring separate administration of multiple agents
3Reliability
If polypeptides with multiple binding moieties are developed, then potency and resistance barrier are improved, but manufacturing complexity increases
Solution Approach 1:
The polypeptides are designed with distinct modular domains (CD4 binding domain, co-receptor binding domain, fusion inhibitor domain) that can be independently optimized and assembled, facilitating standardized manufacturing processes while maintaining high potency and resistance barrier
Solution Approach 2:
The invention optimizes parameters such as domain sequence, linker length and composition, and domain orientation to balance manufacturing feasibility with functional performance, enabling production of complex multi-domain polypeptides using established recombinant protein expression systems
Data Source
AI summary
The invention is directed to polypeptides comprising a CD4 binding moiety, a gp41 binding moiety, a HIV fusion peptide inhibitor moiety and combinations thereof. More specifically, the present invention relates to polypeptides comprising a fibronectin-based scaffold domain protein that binds CD4, a fibronectin-based scaffold domain protein that binds the N17 domain of gp41, and a HIV fusion peptide inhibitor or combinations thereof. The invention also relates to the use of the innovative proteins in therapeutic applications to treat HIV.